Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Motoya

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|May 8, 2008
[Case of ulcerative colitis refractory to intravenous cyclosporine therapy successfully treated with infliximab]Ryosuke Tsuya, Satoshi Motoya, Hiroki Tanaka, et al.
Journal of Gastroenterology|March 18, 2003
Rapidly growing early gastric cancer with microsatellite instabilityKentaro Yamashita, Norihiro Kato, Hiroaki Takahashi, et al.
Journal of Gastroenterology|December 8, 2019
Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trialMakoto Naganuma, Yoko Yokoyama, Satoshi Motoya, et al.
Inflammatory Intestinal Diseases|January 26, 2026
Efficacy and Safety of Ustekinumab in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Subpopulation Analysis of UNIFI Long-Term Extension through 4 YearsHyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, et al.
Inflammatory Bowel Diseases|July 29, 2015
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical TrialYasuo Suzuki, Toshiyuki Matsui, Hiroaki Ito, et al.
Inflammatory Intestinal Diseases|November 27, 2019
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative ColitisYasuo Suzuki, Mamoru Watanabe, Toshiyuki Matsui, et al.
Crohn'S & Colitis 360|December 22, 2025
Post-marketing Surveillance of Tofacitinib in Patients With Ulcerative Colitis in Japan: A Post Hoc Analysis of Safety and Effectiveness by Prior Biologic StatusKatsuyoshi Matsuoka, Satoshi Motoya, Shinichiro Shinzaki, et al.
Advances in Therapy|May 4, 2023
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance StudyKatsuyoshi Matsuoka, Tadakazu Hisamatsu, Yohei Mikami, et al.
Intestinal Research|February 12, 2019
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II studyToshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, et al.
Plos One|August 17, 2018
Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in JapanHitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, et al.
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|May 8, 2008
[Case of ulcerative colitis refractory to intravenous cyclosporine therapy successfully treated with infliximab]Ryosuke Tsuya, Satoshi Motoya, Hiroki Tanaka, et al.
Journal of Gastroenterology|March 18, 2003
Rapidly growing early gastric cancer with microsatellite instabilityKentaro Yamashita, Norihiro Kato, Hiroaki Takahashi, et al.
Journal of Gastroenterology|December 8, 2019
Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trialMakoto Naganuma, Yoko Yokoyama, Satoshi Motoya, et al.
Inflammatory Intestinal Diseases|January 26, 2026
Efficacy and Safety of Ustekinumab in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Subpopulation Analysis of UNIFI Long-Term Extension through 4 YearsHyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, et al.
Inflammatory Bowel Diseases|July 29, 2015
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical TrialYasuo Suzuki, Toshiyuki Matsui, Hiroaki Ito, et al.
Inflammatory Intestinal Diseases|November 27, 2019
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative ColitisYasuo Suzuki, Mamoru Watanabe, Toshiyuki Matsui, et al.
Crohn'S & Colitis 360|December 22, 2025
Post-marketing Surveillance of Tofacitinib in Patients With Ulcerative Colitis in Japan: A Post Hoc Analysis of Safety and Effectiveness by Prior Biologic StatusKatsuyoshi Matsuoka, Satoshi Motoya, Shinichiro Shinzaki, et al.
Advances in Therapy|May 4, 2023
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance StudyKatsuyoshi Matsuoka, Tadakazu Hisamatsu, Yohei Mikami, et al.
Intestinal Research|February 12, 2019
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II studyToshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, et al.
Plos One|August 17, 2018
Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in JapanHitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, et al.
Pageof 9